48 related articles for article (PubMed ID: 15713993)
1. A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer.
Stein SM; Tiersten A; Hochster HS; Blank SV; Pothuri B; Curtin J; Shapira I; Levinson B; Ivy P; Joseph B; Guddati AK; Muggia F
Int J Gynecol Cancer; 2013 Nov; 23(9):1577-82. PubMed ID: 24172094
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.
Ledermann JA; Gabra H; Jayson GC; Spanswick VJ; Rustin GJ; Jitlal M; James LE; Hartley JA
Clin Cancer Res; 2010 Oct; 16(19):4899-905. PubMed ID: 20719935
[TBL] [Abstract][Full Text] [Related]
3. Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer.
Poon C; Duan X; Chan C; Han W; Lin W
Mol Pharm; 2016 Nov; 13(11):3665-3675. PubMed ID: 27712076
[TBL] [Abstract][Full Text] [Related]
4. Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application.
Ye H; Tong J; Liu J; Lin W; Zhang C; Chen K; Zhao J; Zhu W
Oncotarget; 2016 Jul; 7(28):43762-43778. PubMed ID: 27248325
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of single-day GemOx regimen in patients with pancreatobiliary cancer: a single institution experience.
Li J; Merl M; Lee MX; Kaley K; Saif MW
Expert Opin Drug Saf; 2010 Mar; 9(2):207-13. PubMed ID: 20095915
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study.
Demols A; Peeters M; Polus M; Marechal R; Gay F; Monsaert E; Hendlisz A; Van Laethem JL
Br J Cancer; 2006 Feb; 94(4):481-5. PubMed ID: 16434988
[TBL] [Abstract][Full Text] [Related]
7. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study.
López A; Gutiérrez A; Palacios A; Blancas I; Navarrete M; Morey M; Perelló A; Alarcón J; Martínez J; Rodríguez J
Eur J Haematol; 2008 Feb; 80(2):127-32. PubMed ID: 18005385
[TBL] [Abstract][Full Text] [Related]
8. Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.
Vici P; Sergi D; Pizzuti L; Mariani L; Arena MG; Barba M; Maugeri-Saccà M; Vincenzoni C; Vizza E; Corrado G; Paoletti G; Tomao F; Tomao S; Giannarelli D; Di Lauro L
J Exp Clin Cancer Res; 2013 Aug; 32(1):49. PubMed ID: 23927758
[TBL] [Abstract][Full Text] [Related]
9. Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma.
Horowitz NS; Penson RT; Duda DG; di Tomaso E; Boucher Y; Ancukiewicz M; Cohen KS; Berlin S; Krasner CN; Moses MA; Jain RK
Clin Ovarian Cancer Other Gynecol Malig; 2011 Jun; 4(1):26-33. PubMed ID: 21833345
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group.
Ray-Coquard I; Weber B; Cretin J; Haddad-Guichard Z; Lévy E; Hardy-Bessard AC; Gouttebel MC; Geay JF; Aleba A; Orfeuvre H; Agostini C; Provencal J; Ferrero JM; Fric D; Dohollou N; Paraiso D; Salvat J; Pujade-Lauraine E;
Br J Cancer; 2009 Feb; 100(4):601-7. PubMed ID: 19190632
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Kalykaki A; Papakotoulas P; Tsousis S; Boukovinas I; Kalbakis K; Vamvakas L; Kotsakis A; Vardakis N; Papadopoulou P; Georgoulias V; Mavroudis D;
Anticancer Res; 2008; 28(1B):495-500. PubMed ID: 18383891
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine combined with oxaliplatin (GEMOX) as salvage treatment in elderly patients with advanced ovarian cancer refractory or resistant to platinum: a single institution experience.
Germano D; Rosati G; Manzione L
J Chemother; 2007 Oct; 19(5):577-81. PubMed ID: 18073158
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine in patients with ovarian cancer.
Poveda A
Cancer Treat Rev; 2005; 31 Suppl 4():S29-37. PubMed ID: 16360545
[TBL] [Abstract][Full Text] [Related]
14. Role of gemcitabine in ovarian cancer treatment.
Lorusso D; Di Stefano A; Fanfani F; Scambia G
Ann Oncol; 2006 May; 17 Suppl 5():v188-94. PubMed ID: 16807454
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane.
Raspagliesi F; Zanaboni F; Vecchione F; Hanozet F; Scollo P; Ditto A; Grijuela B; Fontanelli R; Solima E; Spatti G; Scibilia G; Kusamura S
Oncology; 2004; 67(5-6):376-81. PubMed ID: 15713993
[TBL] [Abstract][Full Text] [Related]
16. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
Faivre S; Le Chevalier T; Monnerat C; Lokiec F; Novello S; Taieb J; Pautier P; Lhommé C; Ruffié P; Kayitalire L; Armand JP; Raymond E
Ann Oncol; 2002 Sep; 13(9):1479-89. PubMed ID: 12196375
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
